Page 8 - Present Status News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The Over-the-Top Library With a Secret Treasure William O’Connor © Provided by The Daily Beast Alamy It would be understandable if, after taking in the ornate reading rooms and grand hallways of the St. Louis Central Library, you deemed your thirst for literary splendor sated. However, tucked into one of those walls is an elegant but easily missed double door underneath a broken pediment leading to a true treasure trove filled with items that would fetch eye-popping sums at auction. Fittingly, they are books. Not the greatest twist, I suppose, but these are not any old bo...

  of patients with early-stage EGFR-mutated lung cancer   Tagrisso is the only targeted medicine to show efficacy in the treatment of early-stage lung cancer in a global trial and the first such medicine approved in China   where Tagrisso reduced the risk of disease recurrence or death by 80%   AstraZeneca's Tagrisso (osimertinib) has been approved in China for the adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after tumour resection with cu...

  In the ADAURA Phase III trial, chemotherapy use was balanced across the two treatment arms, with 60% of patients receiving prior adjuvant chemotherapy. In line with uptake observed in prior studies and clinical practice, younger patients (

TAGRISSO Approved in the US for the Adjuvant Treatment of Patients With Early-Stage EGFR-mutated Lung Cancer Approval based on unprecedented results from the ADAURA Phase III trial where TAGRISSO WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca’s TAGRISSO ® (osimertinib) has been approved in the US for the adjuvant treatment of adult patients with early-stage epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after tumor resection with curative intent. TAGRISSO is indicated for EGFRm patients whose tumors have exon 19 deletions or exon 21 L858R mutations as ...

ADDING MULTIMEDIA TAGRISSO Approved in the US for the Adjuvant Treatment of Patients With Early-Stage EGFR-mutated Lung Cancer Approval based on unprecedented results from the ADAURA Phase III trial where TAGRISSO WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca’s TAGRISSO ® (osimertinib) has been approved in the US for the adjuvant treatment of adult patients with early-stage epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after tumor resection with curative intent. TAGRISSO is indicated for EGFRm patients whose tumors have exon 19 deletions or exon 21 L...